Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

Westwood, Sarah, Baird, Alison L., Anand, Sneha N., Nevado-Holgado, Alejo J., Kormilitzin, Andrey, Shi, Liu, Hye, Abdul, Ashton, Nicholas J., Morgan, Angharad, Bos, Isabelle, Vos, Stephanie J. B., Baker, Susan, Buckley, Noel J., Ten Kate, Mara, Scheltens, Philip, Teunissen, Charlotte E., Vandenberghe, Rik, Gabel, Silvy, Meersmans, Karen, Engelborghs, Sebastiaan, De Roeck, Ellen E., Sleegers, Kristel, Frisoni, Giovanni B., Blin, Olivier, Richardson, Jill C., Bordet, Régis, Molinuevo, José L., Rami, Lorena, Wallin, Anders, Kettunen, Petronella, Tsolaki, Magda, Verhey, Frans, Lléo, Alberto, Sala, Isabel, Popp, Julius, Peyratout, Gwendoline, Martinez-Lage, Pablo, Tainta, Mikel, Johannsen, Peter, Freund-Levi, Yvonne, Frölich, Lutz, Dobricic, Valerija, Legido-Quigley, Cristina, Bertram, Lars, Barkhof, Frederik, Zetterberg, Henrik, Morgan, B. Paul ORCID: https://orcid.org/0000-0003-4075-7676, Streffer, Johannes, Visser, Pieter Jelle and Lovestone, Simon 2020. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort. Journal of Alzheimer's Disease 74 (1) , pp. 213-225. 10.3233/JAD-190434

Preview

PDF (Creative Commons Attribution Non-Commercial License 4.0) - Published Version Download (164kB) | Preview

Abstract

We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer’s disease (AD) pathology. This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue. Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays. Seven proteins replicated in their ability to predict in vivo amyloid pathology. These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74. The performance of this biomarker panel remained consistent when tested in apolipoprotein E ɛ4 non-carrier individuals only. This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	IOS Press
ISSN:	1387-2877
Date of First Compliant Deposit:	21 October 2020
Date of Acceptance:	27 December 2019
Last Modified:	05 May 2023 22:23
URI:	https://orca.cardiff.ac.uk/id/eprint/135835

Citation Data

Cited 13 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item